Emily Berganini, PA
Medical · Fort Collins, CONPI 1780093641
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,695 of the $9,051 with a category attached, or 62.9%. Johnson & Johnson accounts for 72.7% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $6,645, 4.9 times the $1,356 reported in 2021. Among medical clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $266.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$7K
- Beigene, Ltd.$1K
- Sanofi$246
- AstraZeneca$184
- Pharmacyclics LLC, An Abbvie Company$162
- AbbVie$158
- plus $682 from 8 others
What the payments were for
- Consulting fees$1,04011%
- Speaking & faculty fees$5,69563%
- Travel & lodging$4405%
- Food & beverage$1,87521%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $6,579 |
| Beigene, Ltd. | 1 | $1,040 |
| Sanofi | 2 | $246 |
| AstraZeneca | 2 | $184 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $162 |
| AbbVie | 3 | $158 |
| Incyte Corporation | 2 | $130 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Exelixis Inc. | 1 | $121 |
| Seagen Inc. | 2 | $114 |
| Bristol Myers Squibb | 1 | $93 |
| Beigene USA, Inc. | 1 | $65 |
| Gilead | 1 | $20 |
| Myovant Sciences Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,051 in reported general payments places this provider in the 95th percentile of 766 medical providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 39 | $542,081 |
| JakafiRuxolitinib Phosphate | 31 | $515,329 |
| TasignaNilotinib Hcl | 27 | $324,763 |
| CalquenceAcalabrutinib Maleate | 23 | $324,326 |
| PromactaEltrombopag Olamine | 12 | $287,297 |
| PomalystPomalidomide | 14 | $239,378 |
| ImbruvicaIbrutinib | 13 | $211,688 |
| RevlimidLenalidomide | 11 | $182,110 |
| XtandiEnzalutamide | 11 | $176,352 |
| VenclextaVenetoclax | 22 | $162,826 |
| XareltoRivaroxaban | 21 | $29,696 |
| EliquisApixaban | 12 | $15,362 |
| Acyclovir | 223 | $3,870 |
| Abiraterone Acetate | 22 | $3,156 |
| ValacyclovirValacyclovir Hcl | 20 | $910 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $130 | $515,32931 claims |
| AstraZenecaCalquence | $184 | $324,32623 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $121 | $239,37814 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $162 | $211,68813 claims |
| Bristol Myers SquibbRevlimid | $93 | $182,11011 claims |
| AbbVieVenclexta | $158 | $162,82622 claims |
| Johnson & JohnsonXarelto | $6,579 | $29,69621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 766 medical providers in Colorado.
Other medical in Fort Collins
- Amanda MixonFort Collins$342K
- Michael JacobsonFort Collins$131K
- Brian CronkFort Collins$11K
- Sarah HochFort Collins$8K
- Gregory SimsFort Collins$8K
- Christen KutzColorado Springs$610K
- Kristin RyggColorado Springs$255K
- Jordan MastDenver$247K
- John NovakAurora$173K
- Michelle BarnettColorado Springs$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.